Paul van Midwoud

InGell Labs BV develops polymer-based injectable hydrogels for drug delivery. The firm’s products include InGell LQP, Ingell Gamma, and running in-house projects. It offers its bioabsorbable injectable hydrogel systems for reducing side-effects and localization of novel therapies to life-cycle management opportunities. The company was founded by Paul van Midwoud, Theodorus Adrianus Cornelius Flipsen, Mike G. de Leeuw, and Jan P. M. Hendriks in 2010 and is headquartered in Groningen, the Netherlands.

InGell Labs BV develops polymer-based injectable hydrogels for drug delivery. The firm’s products include InGell LQP, Ingell Gamma, and running in-house projects. It offers its bioabsorbable injectable hydrogel systems for reducing side-effects and localization of novel therapies to life-cycle management opportunities. The company was founded by Paul van Midwoud, Theodorus Adrianus Cornelius Flipsen, Mike G. de Leeuw, and Jan P. M. Hendriks in 2010 and is headquartered in Groningen, the Netherlands.

InGell Labs BV develops polymer-based injectable hydrogels for drug delivery. The firm’s products include InGell LQP, Ingell Gamma, and running in-house projects. It offers its bioabsorbable injectable hydrogel systems for reducing side-effects and localization of novel therapies to life-cycle management opportunities. The company was founded by Paul van Midwoud, Theodorus Adrianus Cornelius Flipsen, Mike G. de Leeuw, and Jan P. M. Hendriks in 2010 and is headquartered in Groningen, the Netherlands.

InGell Labs BV develops polymer-based injectable hydrogels for drug delivery. The firm’s products include InGell LQP, Ingell Gamma, and running in-house projects. It offers its bioabsorbable injectable hydrogel systems for reducing side-effects and localization of novel therapies to life-cycle management opportunities. The company was founded by Paul van Midwoud, Theodorus Adrianus Cornelius Flipsen, Mike G. de Leeuw, and Jan P. M. Hendriks in 2010 and is headquartered in Groningen, the Netherlands.